Abstract: BNG-1, a novel mixture of traditional Chinese medicines with a long history in the treatment of stroke, exhibited acute neuroprotection effect on rats with middle cerebral artery occlusion (MCAO). Anti-ischemic effects were seen in both animals receiving BNG-1 before the ischemic insult as well as in animals receiving the drug formulation after surgical occlusion of the artery. Anti-thrombic activity was seen in vitro to inhibit arachidonic acid-induced platelet aggregation and in vivo to prolong bleeding time in mice. BNG-1 was also found to inhibit several phosphodiesterase (PDE) isoforms with potency order of the following rank: PDE 1 > PDE 3 > PDE 6 > PDE 2 > PDE 4 > PDE 5. Other pre-clinical results and emerging clinical data coupled with the present findings suggest that BNG-1 may be a safe and effective therapy for both the prevention and treatment of cerebral stroke. Moreover, the fundamental cellular mechanism underlying its therapeutic effects may result from phosphodiesterase inhibition.
Introduction
The prevention of primary and secondary recurrent strokes, as well as acute neuroprotection from the ischemic sequelae of stroke, represents major and largely unsatisfied medical needs throughout the world. As a major source of morbidity and mortality, the neurological consequences of stroke are compelling, but difficult targets for pharmacotherapeutic amelioration.
BNG-1 is a formulation of traditional Chinese medicines (TCM) that have been empirically applied to the treatment and clinical management of stroke in southern China and Taiwan for over 300 years (Gong and Sucher, 1999) . This novel mixture is a combination of several Chinese herbs consisting of Scutellariae Radix (6%), Angelicae Radix (12%), Bupleuri Radix (14%), Coptis Rhizome (12%), Bambusae Concretio Silicea (16%), Glycyrrhizae Radix (12%), Ginseng Radix (14%) and Astragali Radix (14%). Some of the active ingredients of these herbs are baicalein in Scutellariae Radix, butylidine phthalide in Angelicae Radix, buplenrumol and saikosides in Bupleuri Radix, berberine and coptisine in Coptis Rhizome, potassium hydroxide in Bambusae Concretio Silicea, glycyrrhizin in Glycyrrhizae Radix, pananosides in Ginseng Radix, and quercetin and isorhamnetin in Astragali Radix. Some of these components have been shown to exert neuroprotective effects through either antithrombotic or anti-inflammatory actions.
Equally important to its history in TCM, BNG-1 has been shown to effectively reduce some of the adverse effects of stroke in recent placebo-controlled phase II studies (personal communication Protech Pharmaservices Corporation). Moreover, BNG-1 is currently being further evaluated to improve recovery from stroke in a large, multi-center phase III study in Taiwan under the sponsorship of Braingenesis Biotechnology, Ltd in partnership with Protech Pharmaservices Corporation.
In this study, we have examined the effects of BNG-1 in a well established animal model of cerebral stroke, namely middle cerebral artery occlusion (MCAO) in rats. We have also conducted a range of studies to reveal and examine the possible pharmacological basis for the established and expanding clinical effectiveness of this novel formulation in the treatment of stroke.
From the results, we speculate that the mechanism underlying the anti-stroke and neuroprotective effects of BNG-1 may be primarily due to the inhibition of phosphodiesterase (PDE), perhaps through a relatively selective inhibition of the PDE 1 isoform in this family.
Materials and Methods

Animals
In this study, male Sprague Dawley derived rats, male/female ICR mice, New Zealand albino male/female rabbits and male/female Duncan Hartley guinea pigs were used (animal breeding center of MDS Pharma Services Taiwan, Ltd). Animals were allowed access to standard lab chow and were maintained under a controlled temperature (22-24 o C) and humidity (60%-80%) environment with 12-hour light-dark cycles for at least one-week prior to use. 6 3 THE NEUROPROTECTIVE EFFECTS OF BNG-1 Chemicals BNG-1 was formulated and the dried raw materials grinded to a very fine powder provided from Braingenesis Biotechnology, Ltd. Chloral hydrate, MK-801, aspirin, arachidonic acid 90% sodium salt, epinephrine bitartrate, (±) isoproterenol hemisulfate salt, 3-isobutyl-1-methylxanthine (IBMX) and indomethacin are purchased from Sigma Chemical Co. (St. Louis MO USA).
Bleeding Time
A group of five ICR derived male mice weighing 22 ± 2 g received BNG-1 at a dose of 1 g/kg per day for 7 days. One final dose of 1 g/kg was administered orally 1 hour before transection of the tip (0.5 mm) of each tail on the 8th day.
The mice, restrained in holders, were immediately suspended vertically with the distal 2 cm of each tail immersed in a test tube containing saline at 37°C. The time required for bleeding to cease was then determined with a maximum cut-off time of 180 seconds (Buteler et al., 1982) . Prolongations of bleeding time were expressed as a percentage relative to a control group of animals.
Arachidonic Acid-Induced Platelet Aggregation
Venous blood obtained from male or female New Zealand derived albino rabbits weighing 2.5-3 kg was used. Blood samples were mixed with one-tenth volume of trisodium citrate (0.13 M) and centrifuged at room temperature for 10 minutes at 220 g. The effect of BNG-1 (1000 µg/ml) was evaluated at 37°C with an aggregometer to inhibit arachidonic acid (100 µM)-induced aggregation of the platelet rich plasma (6 × 10 8 platelets/ml) in an all-or-none manner with a maximum cut-off time of 5 minutes (Bertele et al., 1983) .
Isolated Guinea Pig Trachea
Tracheal rings obtained from Duncan Hartley derived male or female guinea pigs weighing 325 ± 25 g were used. The tissues were placed under 1 g tension in a 10 ml bath containing Krebs solution pH 7.4 at 37°C and allowed to develop spontaneous tone (Lundblad et al., 1988) . BNG-1 (1000 µg/ml)-induced relaxations expressed as a percentage, relative to maximal response elicited by 1.6 µM epinephrine, of maximum within 7 minutes following exposure were recorded and compared.
Isolated Guinea Pig Left Atria
Left atria obtained from Duncan Hartley derived male or female guinea pigs weighing 325 ± 25 g were used. The tissues were placed under 1 g tension in a 10 ml bath containing Tyrode's solution pH 7.4 with one-third normal (0.6 mM) calcium at 32°C and subjected to field stimulation (70% of maximum voltage, 1.5 Hz, 0.2 msec) (Erjavek and Adamic, 1965) . BNG-1 (1000 µg/ml)-induced positive inotropic responses expressed as a percentage, relative to 50 nM isoproterenol responses, within 5 minutes following drug exposure were recorded and compared.
Phosphodiesterase Inhibition Assays
PDE 1 partially purified from bovine heart was used. BNG-1 or vehicle was incubated with 13 µg enzyme, 1.0 µM cold AMP with [ 3 H]-cAMP and CaCl 2 /calmodulin in Tris buffer pH 7.5 for 20 minutes at 30°C. The reaction was terminated after 2 minutes of boiling. The resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30°C for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [ 3 H]-adenosine in the aqueous phase was quantitated by scintillation counting.
The assays of PDE 2, PDE 3, PDE 4, PDE 5 and PDE 6 were similar to PDE 1, the differences of enzyme source, enzyme amount, cold cAMP/cGMP, [ 3 H]-cAMP/[ 3 H]-cGMP and quantitation were listed below (Hidaka and Asano, 1976; Nicholsen et al., 1991; Cortijo et al., 1993; Baehr et al., 1979; Gillespie and Beavo, 1989 A permanent brain ischemia was achieved by MCAO in male Sprague Dawley rats weighing 180-240 g under chloral hydrate (500 mg/ml/kg IP) anesthesia (Tamura et al., 1981; Cao and Phillis, 1994) . The temporoparietal region was shaved and a skin incision was made between the lateral aspect of the orbit and the external acoustic meatus. The superior pole of the parotid gland was reflected downwards as was the temporalis muscle after partial resection of its cranial insertion. The distal course of the middle cerebral artery was then visible through the translucent skull.
Under a 10 × magnifying stereomicroscope, craniectomy was performed with a dental drill and then enlarged with fine synovectomy rongeurs. The middle cerebral artery at the proximal site of branching originating from the interior carotid artery was cut with microscissors, the temporalis muscle and parotid gland were replaced. The incision was lightly dusted with kanamycin, the scalp was sutured and a 10% povidone iodine solution 6 5 THE NEUROPROTECTIVE EFFECTS OF BNG-1 was topically applied. During surgery, the animals were maintained normothermic at 37.5 ± 1.0°C by a heating system coupled to a rectal thermistor probe.
After surgery, animals were kept in an infant incubator for 1 hour. After recovery, the rats were housed five per cage with free access to food and water and kept in a clean animal room (23.0 ± 1.0°C).
Dosing Regimes
Two separate drug treatment protocols were employed in separate groups of experiments.
Protocol A: Animals were treated both prior to and after MCAO as follows: BNG-1, dissolved in saline as vehicle, was administered at doses of 1 g/kg or 0.5 g/kg orally (PO) in a dosing volume of 10 ml/kg daily for 7 consecutive days before and for 3 days after MCAO. The vehicle-control group was similarly treated with saline alone. The positive control reference agent MK-801 dissolved with saline was injected at a dose of 0.3 mg/kg intraperitoneally (IP) in a dosing volume of 5 ml/kg at 0, 6, 24, 30, 48 and 54 hours after MCAO.
Protocol B: Animals were treated only post-surgical MCAO as follows: BNG-1, dissolved in saline as vehicle, was administered at doses of 1 g/kg orally (PO) in a dosing volume of 10 ml/kg daily for 7 consecutive days immediately after MCAO. The vehicle-control group was similarly treated with saline alone. The positive control was the same as described in protocol A.
On the 8th day after the ischemic insult, all animals were sacrificed by decapitation. Their brains were rapidly removed and immediately frozen at −70°C in a deep freezer (NUAIR TM , NU-6511). Twenty-four hours later, whole brain coronal sections (30 µm) were obtained by use of a microtome ("SHANDON" Varistain 24-4 Automatic Slide). Every 13th section (i.e. 390 µm apart), covering the infarction area of 12 mm length was selected for histological examination. The total of 30 slices, stained with 2% cresyl violet, was used to measure the area of ischemic damage. This was quantitatively assessed by an Image Analyzer. The total ischemic area (mm 2 ) of each coronal slice from each animal was summated and expressed as the mean ± SEM. The calculated infarcted volume in mm 3 (area × distance) was then expressed as the mean ± SEM for each experiment group. The effect of BNG-1 was calculated for comparison with the vehicle control group by means of the unpaired Student's t test. Differences were considered significant when * P < 0.05.
Results
Administration of BNG-1 at a dose of 1 g/kg daily for 8 consecutive days in vivo caused a 60.4% increase bleeding time in mice, compared to that of control animals (Table 1) . BNG-1 at 300 µg/ml or higher in vitro inhibited arachidonic acid-induced rabbit platelet aggregation in an all-or-none manner (Table 2) . BNG-1 at a concentration of 300 µg/ml and 1000 µg/ml caused 17.8% and 59.8% tracheal relaxation of this smooth muscle preparation, respectively, compared to the control tissues (Table 3 ). In addition, BNG-1 at 1000 µg/ml Arachidonic acid (100 µM)-induced platelet aggregation response within 5 minutes. N = 4 for each concentration. Inhibition represents in an all-or-none manner. Table 3 .
Effects of BNG-1 on Contractility-Tracheal in Guinea Pig
Treatment Concentration (µ µ µ µ µg/ml) Relaxation (%) Vehicle 0.1 ml 0 ± 0 Epinephrine 1.6 µM 100 ± 0 BNG-1 1000 59.8 ± 4.7 300 17.8 ± 4.7 100 0 ± 0 Epinephrine (1.6 µM)-induced tracheal relaxation was set as 100% response with respect to basal tone (set as 0%). N = 4 for each concentration. Each value represents mean ± standard error. Figure 2. The vehicle control (Saline, 10 ml/kg, n = 10, PO) and BNG-1 (1000 mg/kg, n = 10, PO) daily treatment for 10 consecutive days beginning 7 days before and 3 days after MCAO. The surface of the ischemic lesion was measured in cresyl violet 2% stained serial sections using a VISTA version 3 Image Analysis System. Infarcted volumes (mean ± SEM) under different treatments are shown. The effect of BNG-1 was calculated for comparison with the vehicle control group by means of the unpaired Student's t test. Differences were considered significant when * P < 0.05. Figure 3 . The vehicle control (Saline, 10 ml/kg, n = 10, PO) and BNG-1 (500 mg/kg, n = 10, PO) daily treatment for 10 consecutive days beginning 7 days before and 3 days after MCAO. The surface of the ischemic lesion was measured in cresyl violet 2% stained serial sections using a VISTA version 3 Image Analysis System. Infarcted volumes (mean ± SEM) under different treatments are shown. The effect of BNG-1 was calculated for comparison with the vehicle control group by means of the unpaired Student's t test. Differences were considered significant at * P < 0.05. caused increases in contractility of guinea pig cardiac left atria by 30.5% (Table 4) . BNG-1 had inhibitory effects on PDE 1 (IC 50 = 24.0 µg/ml), PDE 2 (IC 50 = 260.9 µg/ml), PDE 3 (IC 50 = 67.9 µg/ml), PDE 4 (IC 50 = 301.3 µg/ml), PDE 5 (IC 50 = 457.7 µg/ml) and PDE 6 (IC 50 = 176.5 µg/ml) ( Table 5) .
Under Protocol A, BNG-1 at doses of 1 g/kg and 0.5 g/kg orally administered for 10 consecutive days beginning 7 days before and 3 days after MCAO rats caused a 44% and 14% inhibition of cerebral infarct volumes, respectively (Figs. 1 to 3) . With Protocol B, same doses of BNG-1 administrated for 7 consecutive days immediately after MCAO caused a 55.8% inhibition on the total volume of ischemic lesions with respect to animals receiving only vehicle (Figs. 1 and 4) .
Discussion
This study suggests that BNG-1 may prove to be clinically useful in affording neuroprotective effects subsequent to cerebrovascular stroke. Additionally, BNG-1 may also prove to be of therapeutic value in the prevention of primary or recurrent strokes in susceptible patient populations. Thus, this formulation of TCMs exhibited anti-thrombic effects in vivo and in vitro to prolong mice bleeding time and to inhibit arachidonic acid-induced platelet aggregation. These effects are shared by previously well-documented actions of aspirin, dipyridamole and clopidogrel, all of which are of established therapeutic benefit in the prevention of recurrent, and possibly initial strokes (Feldman and McNamara, 2002) . With regard to acute neuroprotection, animals treated with BNG-1 daily for 7 consecutive days Figure 4 . The vehicle control (Saline, 10 ml/kg × 7, n = 10, PO) and BNG-1-treated rats (1000 mg/kg × 7, n = 10, PO) after MCAO for 7 consecutive days. The surface of the ischemic lesion was measured in cresyl violet 2% stained serial sections using a VISTA version 3.0 Image Analysis System. Infarcted surface areas (mean ± SEM) are shown. The effect of BNG-1 was calculated for comparison with the vehicle control group by means of the unpaired Student's t test. Differences were considered significant at * P < 0.05. before and for 3 days after ischemic insult, as well as in animals treated for 7 consecutive days post-MCAO, were found to have significant reductions in brain infarct volume. This action suggests that BNG-1 might be clinically effective in reducing the extent of neuronal damage, when administered subsequently to stroke incidents in humans. Indeed, clinical evidence based both on the substantial history of BNG-1 components as TCMs and ongoing controlled clinical trials, already exist to support this hypothesis.
In regards to a possible mechanistic basis of the neuroprotective and anti-stroke effects of BNG-1, it may be that these actions, and other observed pharmacological effects, ultimately derive from inhibition of brain and/or vascular phosphodiesterase enzymatic activities. BNG-1, in addition to the effects noted above, caused relaxations of the contractility of isolated guinea pig trachea and exerted a modest positive inotropic activity on isolated guinea pig left atria. All of these effects are consonant with and could be mediated through the direct inhibitory effects observed through BNG-1 on various isoforms of PDE. That significant neuroprotection or stroke prevention might obtain from PDE inhibitory effects are not new concepts. Several PDE inhibitory compounds, such as sildenafil (Zhang et al., 2002) , vinpocetin (Vas et al., 2002) , ibudilast (Kishi et al., 2001) , propentofylline (Johnson et al., 1998) , and others (Feldman and McNamara, 2002) have been shown to possess in vivo cerebral anti-ischemic effects. Importantly, the novel PDE 3 selective inhibitor, cilostazol, has been shown to be highly effective in preventing secondary cerebral infarction in controlled clinical trials (Gotoh et al., 2000) . Although it is not entirely evident as to which of the major PDE isoforms predominates in the pathogenesis of stroke and subsequent neurodegeneration, it is noteworthy that both vinpocetin and BNG-1 appear to be relatively selective inhibitors of the PDE-1 isoform in the PDE family.
We have also conducted an extensive safety pharmacology assessment of high doses of BNG-1 in a battery of tests to determine other possible effects of this TCM on important mammalian physiological systems (manuscript in preparation).
In brief, these findings demonstrated that there are no threats to the normal vital functions of the cardiovascular, renal, respiratory or central nervous systems in the animals. In addition, high doses of BNG-1 did not influence blood glucose or cholesterol levels and had no effects on carrageenan-induced paw edema or skeletal muscle tone either. This further suggests that BNG-1 does not exert acute adverse pharmacological effects in a clinical setting. This apparent safety and tolerability of BNG-1 appears to be substantiated in the long history of component herbs of BNG-1 used as folk TCMs and in the controlled clinical trials to date (personal communication with Protech Pharmaservices Corporation).
